NCT05202041Unknown不适用
Diagnostic Performance and Prognostic Ability of AccuFFRangio for Non-IRA in NSTE-ACS Patients
适应症
试验速览
- 阶段
- 不适用
- 入组人数
- 500
- 主要终点
- Vessel-oriented composite endpoints (VOCEs)
研究概览
简要总结
This is a prospective, single-center clinical trial. AccuFFRangio (ArteryFlow Technology Co., Ltd., Hangzhou, China) is a novel method for evaluating the functional significance of coronary stenosis by computing the pressure in the vessel based on angiographic images. The purpose of this study is to investigate the diagnostic performance and prognostic ability of AccuFFRangio for non-IRA in NSTE-ACS patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18 Years and older
- •Non-ST-segment elevation acute coronary syndrome patients with at least 1 non-IRA
- •Diameter stenosis of 50%-90% by visual estimate
- •Reference vessel size > 2 mm in stenotic segment by visual estimate
排除标准
- •LVEF ≤ 40%
- •eGFR < 60 mL/min
- •Allergy to contrast media, adenosine
- •Prior CABG
结局指标
主要结局
Vessel-oriented composite endpoints (VOCEs)
时间窗: 1 year
Composite of vessel-related cardiovascular death, vessel-related myocardial infarction, and ischemia-driven target vessel revascularization.
Post-PCI AccuFFRangio
时间窗: 1 year
AccuFFRangio limits to yield no VOCEs.
次要结局
- Cost analysis(1 year)
研究者
相似试验
Unknown
不适用
Prognostic Implications of AccuFFRangio-guided PCI in STEMIST Elevation Myocardial InfarctionCoronary Artery DiseaseNCT05209503Wuhan Asia Heart Hospital500
招募中
不适用
Improving Hepatocellular Carcinoma ScreeningMagnetic Resonance ImagingScreeningContrast-enhanced USHepatocellular CarcinomaNCT05828446Naik Vietti Violi330
已完成
不适用
Confocal Laser Endomicroscopy Guided Cryobiopsy in the Diagnosis of Interstitial Lung DiseaseMultiple Pulmonary NoduleSolitary Pulmonary NoduleInterstitial Lung Disease (ILD)NCT06741826China-Japan Friendship Hospital430
已完成
不适用
FFRangio Accuracy vs. Standard FFRCoronary Artery DiseaseNCT03226262CathWorks Ltd.382
已完成
2 期
A prospective study to assess additional benefit of Fluorodeoxyglucose (FDG) PET scanning after staging with Prostate Specific Membrane Antigen (PSMA) PET for newly diagnosed high grade prostate cancerCancer - ProstateProstate cancerACTRN12621001185853Metro North Hospital and Health Service32